[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"migraine-headache-with-or-without-aura\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:migraine-headache-with-or-without-aura":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100619758","yogabased-movements-for-primary-headaches-migraine-andor-cluster-headache---yourhead-100619758",false,"NCT07348783","Yogabased Movements for Primary Headaches (Migraine and\u002For Cluster Headache) - YOURHEAD","Yogabased Movements Weekly (Online Live or Face to Face) for Primary Headaches","Inclusion Criteria:\n\n* Diagnosed chronic migraine and\u002For cluster (Hortons) headache\n* Men and women 18-65 years\n* Diagnosed with chronic\u002Fhigh frequency migraine (≥15 headache days\u002Fmonth with at least ≥8 with migraine)\n* Diagnosed with chronic cluster head ache (i.e shorter remission than 3 months per year), diagnosed according to ICHD-III criteria.\n* Ability to perform yoga based moments and to give consent.\n* Internet connection with computer\u002Fipad\u002Fmobile to perform digitally\u002Ftele-health instructions\n* Willing to use wristwatch for actigraphy\n* Willing to leave blood samples in laboratory\n\nExclusion Criteria:\n\n* Recent or planned operations during the last 6 weeks\n* Drug dependence, alcohol dependence, mental disorders as psychosis, bipolar disorder, anxiety as PTSD etc)\n* Parallel enrollment in other clinical trails\n* Unmedicated high blood pressure, heart disease as heart failure\n* Non Swedish speaking\n* Not able to perform low intensity exercise at home or FTF (face to face) - both online or live.\n* Participants unsure to participate due to drug addiction or other causes\n* Disorientation and not able to inform regarding other serious conditions","ALL","18 Years","65 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Brief Summary:\n\nMigraine and\u002For Cluster Headache: Study Overview\n\n\\*\\*Background:\\*\\* Migraine and cluster headache are two primary headache disorders that significantly impact quality of life and functionality in those affected. According to the WHO's recurring burden of disease reports, migraine is among the neurological conditions responsible for the highest number of years lost due to illness. The headaches associated with migraine and cluster headache range from moderate to severe and cause great suffering. Available treatments do not work for everyone and are often associated with adverse side effects. Physical activity has been shown in several studies to have a positive effect on headache. Given the high prevalence of mental health issues, stress, and sleep problems within this patient group, relaxation and low-intensity exercise such as yoga-based movements (YB) could potentially help individuals improve sleep and well-being, while also providing some preventive effect on headaches.\n\n\\*\\*Hypothesis:\\*\\*\n\nIndividuals with severe migraine or cluster headache have a strong need for new treatment options. Alternative therapies such as yoga-based exercises, when combined with standard medical treatment as per clinical guidelines, may positively impact:\n\nHeadache symptoms, Sleep quality and Overall life quality\n\n* Purpose and Goals:\\*\\* This randomized controlled study aims to evaluate the effect of a web-based yoga (YB) or live face to face (FTF) intervention in individuals suffering of primary headaches-mainly chronic migraine and\u002For cluster headache. The study will assess the effect of YB on health-related changes in headache frequency, intensity, and duration associated with primary headache conditions, with a focus headache frequency. A secondary objective is to analyze quality of life, sleep quality, mental health as depression and anxiety. The RCT will also measure objective sleep and biomarkers. We are now summarizing the effects after a pilot study.\n* Relevance for the Patient Group:\\*\\* The core objective of the project is to determine whether yoga-based exercises can serve as a complementary treatment to enhance quality of life and health in patients with severe primary headache. To ensure equal healthcare access, this intervention will be delivered in digital format and\u002For FTF to optimize availability and expand care for individuals with primary headache disorders. These efforts aim to improve life quality and well-being in a vulnerable patient population. Headache conditions often affect individuals in their most productive years, and many live with symptoms for decades. Both work and private life are frequently disrupted, resulting in sick leave and social isolation. Close relatives are also affected, as those suffering from headaches require more recovery time to cope with daily life. With this proposed project, we aim to use physical yoga, rooted in holistic traditional medicine, to help individuals with severe primary headache achieve better physical and mental health-particularly improved sleep quality, which in turn enhances overall life quality.",[27,28,29,30,31,32],"Cluster Headache - Episodic and Chronic","Migraine Headache","Migraine Headache, With or Without Aura","Migraine in Adults","Cluster Headaches and Other Trigeminal Autonomic Cephalgias","Migraine Disorder","RECRUITING","2026-06-23",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":37},"2026-05-01",{"date":41,"type":21},"2027-12-30",{"name":43,"class":44},"Karolinska Institutet","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100531751","a-comparison-of-biodegradable-and-metal-occluders-in-patients-with-pfo-and-migraine-100531751","NCT06203873","A Comparison of Biodegradable and Metal Occluders in Patients With PFO and Migraine","BioMetal","Inclusion Criteria:\n\n1. Age 18-65\n2. Diagnosed migraine by ICHD-3\n3. History of migraine longer than 1 year, and symptoms severely disturbing daily life.\n4. TCD\u002FTTE\u002FTEE diagnosed patent foramen ovale with right to left shunt\n5. Willing to participant and agree to follow-ups\n6. Received at least three different types of migraine preventive drugs, the responder rate of previous therapy did not receive 50%.\n\nExclusion Criteria:\n\n1. Migraine caused by other reason\n2. Had TIA\u002Fstroke history\n3. With contraindication or hypersensitive to anti-platelet or anticoagulation drugs.\n4. With contraindication to PFO occlusion",{"count":54,"type":21},400,[24],"Migraine is one of the most common chronic neurological disorders, posing a significant global public health concern. Patent Foramen Ovale (PFO) is the most common congenital heart anomaly in adults. Mechanisms linking PFO to migraine include cortical spreading depression, vascular active substance theory, impaired cerebral autoregulation, and genetic susceptibility. Understanding these mechanisms holds promise for overcoming challenges in the prevention and treatment of migraines in PFO patients. At least 11 observational studies, comprising 1,632 subjects, described the efficacy of PFO closure in cryptogenic stroke. Of these, 34% had migraines, and percutaneous PFO closure reportedly reduced migraine days by 81% (with a reduction of over 50% in monthly migraine days). Prospective randomized controlled trials (PRIMA and PREMIUM trials) assessing the Amplatzer® PFO Occluder showed significant benefits in most secondary endpoints, with a pooled analysis indicating its safety and effectiveness compared to medical therapy.While traditional metal PFO closure studies suggest symptom relief, reports also mention potential new-onset or worsened migraines post-closure. Proposed mechanisms include platelet activation, microthrombus formation, nickel allergy, and septal deformation or stretching inducing the release of migraine-related vascular active substances. However, these theories are closely tied to the presence of permanent metal implants.\n\nAddressing these concerns, the MemoSorb® biodegradable PFO Occluder system, approved by the National Medical Products Administration (NMPA) in September 2023, offers an innovative solution. Developed collaboratively by the National Biomedical Materials Engineering Technology Research Center, Professor Wang Yunbing\\'s team, Professor Pan Xiangbin\\'s team from Fuwai Hospital, Chinese Academy of Medical Sciences, and HeartTech Medical, this groundbreaking technology represents a shift from metal to degradable materials. The occluder serves as a temporary bridge post-implantation, gradually degrading with endothelialization, facilitating comprehensive self-repair. This intervention concept theoretically avoids the lifelong complications associated with traditional metal occluders, effectively reducing postoperative symptoms like migraines and dizziness.\n\nTo assess and compare the treatment outcomes, especially in relieving migraines, a prospective, single-blind, randomized controlled study has been designed for patients with patent foramen ovale and migraine, comparing the novel biodegradable occluder with the metal occluder.",[58,59,28,29],"PFO - Patent Foramen Ovale","Migraine","2025-11-27",{"date":62,"type":37},"2025-12-04",{"date":64,"type":37},"2024-03-01",{"date":66,"type":21},"2026-03-01",{"name":68,"class":44},"Chinese Academy of Medical Sciences, Fuwai Hospital",2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":45},"100594672","phase-4-assessment-of-oral-caffeine-intake-in-changing-the-severity-of-acute-migraine-attack-using-vas-score-among-patients-attending-headache-and-neurology-outpatients-clinic-of-ainshams-university-hospitals-100594672","NCT07022496","Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals","Assessment of Oral Caffeine Intake in Reducing the Severity of Acute Migraine Attack Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals: A Randomized Controlled Trial","Inclusion Criteria:\n\nPatients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study.\n\nExclusion Criteria:\n\nPatients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded","60 Years",{"count":79,"type":21},120,[81],"PHASE4","Caffeine extracted from green tea to abort acute attack of Migraine",[59,84,28,29,85],"Migraine Disease","Migraine, Acute","2025-06-07",{"date":88,"type":37},"2025-06-15",{"date":90,"type":37},"2023-04-26",{"date":92,"type":21},"2025-08",{"name":94,"class":44},"Ain Shams University"]